Replimune Posts Q2 FY2027 Results: First TUDRIQEV Launch Metrics, $307.8M Cash
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune's first post-approval quarter shows TUDRIQEV in use at more than 15 institutions and 70%-plus of priority accounts engaged, with $307.8M in cash and a narrower $57.1M net loss. No product revenue was disclosed.
Key Events · Earnings and Guidance · REPL
-
First TUDRIQEV Launch Metrics Disclosed
TUDRIQEV was first delivered to patients on October 6, 2026; more than 15 institutions have prescribed it and the company has engaged over 70% of its initial 200 priority accounts.
-
Cash Rises to $307.8M
Cash and cash equivalents were $307.8M at September 30, 2026 versus $268.9M at March 31, 2026, after roughly $141.0M in net August offering proceeds and a $15.0M tranche 4 debt draw.
-
Loss Narrows on Lower R&D
Net loss was $57.1M versus $83.1M a year earlier; R&D fell to $34.4M from $57.9M and SG&A to $21.9M from $26.4M.
-
Runway Beyond Twelve Months
Management expects existing cash to fund operations for greater than twelve months, including TUDRIQEV commercialization.
Analysis · REPL · Life Sciences
This is the first quarterly report since TUDRIQEV won accelerated approval in August, so it offers the first read on whether the launch is working. Management says more than 15 institutions have already prescribed the drug and over 70% of the initial 200 priority accounts have been engaged, with more than a year of inventory on hand. The loss narrowed to $57.1M from $83.1M a year ago as R&D fell to $34.4M from $57.9M, and cash rose to $307.8M from $268.9M at fiscal year-end after the August raise and a $15.0M debt draw. That funds operations for more than twelve months, per the company. No revenue figure is disclosed in the release, so the actual sales ramp is not yet quantified — the confirmatory IGNYTE-3 trial, which underpins continued accelerated approval, remains the key binary risk.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REPL was trading at $12.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.50 to $16.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.